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Abstract
© 2018, Pediatria Ltd.. All rights reserved. The course and prognosis of cystic fibrosis (CF) in
many ways depend on the degree of bronchopulmonary system lesion. Important role in the
development of chronic inflammation in the bronchopulmonary system belongs to conditionally
pathogenic microorganisms. Rational  antibiotic  therapy (ABT) allows to restrain the natural
course of  the disease.  How ever,  wide spread use of  antibiotics (AB) creates problems of
microorganisms' resistance. The article reviews the literature on antibacterial resistance (ABR)
development mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa, which most
often colonize the respiratory tract in CF. Staphylococcus aureus and Pseudomonas aeruginosa
ABR realizes by the mechanisms of natural and acquired resistance. The acquired resistance of
bacteria develops as a result of natural selection through random mutations and/or through the
action  of  antibacterial  drugs.  Microorganisms  carry  genetic  information  of  resistance  to
antibiotics  by  horizontal  gene  transfer,  which  threatens  the  spread  of  multidrug  resistant
bacteria strains. Rational ABT is a key mechanism for restraining the development of bacteria
antibiotic resistance.
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